Poster Presentations Session II
Poster Presentations Session II Sunday, 17 September 2017
POSTERS SET-UP: 7:45 - 8:00
POSTERS DISPLAY HOURS: 8:00 - 14:00
POSTER AUTHOR DISCUSSION: 13:00 - 14:00
POSTERS DISMANTLE: 14:00


Poster display locations are shown below the poster codes
CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies
PCV1
D16
SYSTEMATIC REVIEW OF STATINS EFFECTIVENESS IN PREVENTION SECONDARY IN ELDERLY
Shoshima AY1, Costa MG2, Tura BR2
1Secretaria Municipal de Saúde Santana de Parnaíba, Santana de Parnaiba, Brazil, 2Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil

PCV2
D17
AN ASSESSMENT OF CORRELATION BETWEEN MORTALITY AND DISTANCE FROM PATIENT’S RESIDENCE TO INTERVENTIONAL CENTER IN PERCUTANEOUS CORONARY INTERVENTION IN BRAZIL
Matsumoto YK1, Campos DF1, Rosim RP1, Duva AS1, Hirth WA1, Ballalai Ferraz AF1, Braile DM2
1QuintilesIMS, São Paulo, Brazil, 2FAMERP, São José do Rio Preto, Brazil

CARDIOVASCULAR DISORDERS - Cost Studies
PCV3
D18
BUDGET IMPACT ANALYSIS OF ADOPTING EVOLOCUMAB IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM FOR PATIENTS WITH UNCONTROLLED LDL-C AND HIGH CARDIOVASCULAR RISK
dos Santos RF1, Alves FP1, Urbich M2, Villa G2, Farsky PS3
1Amgen, São Paulo, Brazil, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Instituto Dante Pazzanese de Cardiologia (IDPC), São Paulo, Brazil

PCV4
E1
COSTO DE EVENTOS CORONARIOS AGUDOS EN POBLACIÓN CON FACTORES DE RIESGO CARDIOVASCULAR: ANÁLISIS RETROSPECTIVO.
Romero Prada ME, Huerfano LM, Vasquez Melo EC
Fundación Salutia, Bogotá, Colombia

PCV5
E2
IMPACTO ECONÓMICO DE LA FIBRILACIÓN AURICULAR EN UNA ASEGURADORA COLOMBIANA
Romero Prada ME1, Lancheros J2, Alfonso Quiñones PA3, Marrugo Figueroa RD4, Peñuela IA4, Mendoza F5, Herran Diazgranado SE4
1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, 3Salutia Foundation, Bogotá, Colombia, 4Bayer, Bogotá, Colombia, 5Clinica Shaio, Bogota, Colombia

PCV6
E3
COSTO Y CONSUMO DE RECURSOS DE PACIENTES POSTERIOR A ENFERMEDAD CEREBROVASCULAR EN COLOMBIA
Mendoza-Sanchez J, Silva F, Arias J, Pachon M, Ortiz C
Fundación Cardiovascular de Colombia, Floridablanca, Colombia

PCV7
E4
AN OBSERVATIONAL CROSS-SECTIONAL DATABASE STUDY TO ESTIMATE HOSPITALIZATION COSTS RELATED TO CARDIOVASCULAR DISEASE IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM
dos Santos RF1, Alves FP1, Manfrin DF1, Sampaio M1, Caltabiano RH1, Paloni Ed2, Paiva EC2
1Amgen, São Paulo, Brazil, 2Orizon, Barueri, Brazil

PCV8
E5
COST-UTILITY OF PRASUGREL COMPARED TO CLOPIDOGREL FOR PREVENTING CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME IN BRAZIL
Rosim RP1, Litmanowicz TM1, Ballalai Ferraz AF1, Arbeleche S1, Teixeira R2, Ebel R2
1QuintilesIMS, São Paulo, Brazil, 2Daiichi Sankyo, São Paulo, Brazil

PCV9
E6
COST-EFFECTIVENESS ANALYSIS OF A PHARMACEUTICAL CARE PROGRAM FOR SYSTEMIC ARTERIAL HYPERTENSION CARE INTO BRAZILIAN PUBLIC HEATH SYSTEM
Cazarim MS, Nunes AA, Pereira LR
University of São Paulo, Ribeirão Preto, Brazil

PCV10
E7
ECONOMIC IMPACT OF FLOSEAL IN CARDIAC SURGERY FROM THE PERSPECTIVE OF THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
Jimenez P1, Ramirez MG2, Ikeme S3, Lemus F4, Figueroa A4
1Baxter, Mexico City, Mexico, 2Baxter, Mexico city, Mexico, 3Baxter Healthcare Corporation, Deerfield, IL, USA, 4Pharmamanagement EAS S de RL de CV, Cuidad de México, Mexico

PCV11
E8
COST-EFFECTIVENESS ANALYSIS OF A RANDOMIZED TRIAL OF AN MHEALTH INTERVENTION TO IMPROVE CARDIOMETABOLIC PROFILE IN PREHYPERTENSIVE SUBJECTS FROM LOW-RESOURCE URBAN SETTINGS IN LATIN AMERICA
Augustovski F1, Palacios A1, Beratarrechea A1, Diez-Canseco F2, Irazola V1, Ramirez-Zea M3, Pichon-Riviere A1, Rubinstein A1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru, 3INCAP Research Center for the Prevention of Chronic Diseases (CIIPEC), Institute of Nutrition of Central America and Panama, Guatemala, Guatemala

PCV12
E9
COSTO EFECTIVIDAD DEL USO DE TICAGRELOR FRENTE A COPIDOGREL EN PACIENTES CON SÍNDROME CORONARIO AGUDO EN COLOMBIA
Romero Prada ME1, Roa Cardenas NC2, Huerfano LM1
1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia

PCV13
E10
COST EFFECTIVE ANALYSIS OF PHARMACEUTICAL CARE IN MANAGEMENT OF PATIENTS WITH STAGE III HYPERTENSION: AN INDIAN PHARMACISTS EXPERIENCE
Parimalakrishnan S, Jainaf Nachiya R, Anton Smith A, Mohanta GP, Manna PK
Annamalai University, Chidambaram, India

CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PCV14
E11
ADESÃO A TERAPIA ANTIHIPERTENSIVA E QUALIDADE DE VIDA
Yamaguchi MU1, Ramos RN2, Souza AO2, Ramos ER3
1Instituto Cesumar de Ciência, Tecnologia e Inovação, Maringá, Brazil, 2Centro Universitário de Maringá - UniCesumar, Maringá, Brazil, 3Universidade Federal de Sergipe, Aracajú, Brazil

PCV15
E12
ASSESSING THE BURDEN OF CHRONIC HEART FAILURE (CHF) ON PATIENTS’ CAREGIVERS IN ARGENTINA
Bianculli PM1, Jackson J2, Cotton S2, Proenca C3, Calado F3, MacPherson A4, Barbeau M5
1Novartis Argentina S.A., Buenos Aires, Argentina, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada, 5Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV16
E13
ASSESSING THE BURDEN OF CHRONIC HEART FAILURE (CHF) ON PATIENTS’ CAREGIVERS IN MEXICO
Romo X1, Jackson J2, Cotton S2, Proenca C3, Calado F3, MacPherson A4, Barbeau M5
1Novartis Farmacéutica S.A. de C.V, Mexico City, Mexico, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada, 5Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV17
E14
ASSESSING THE BURDEN OF CHRONIC HEART FAILURE (CHF) ON PATIENTS’ CAREGIVERS IN BRAZIL
Lopes N1, Jackson J2, Cotton S2, Proenca C3, Calado F3, MacPherson A4, Barbeau M5
1Novartis Biociências SA, Sao Paulo, Brazil, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada, 5Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV18
E15
ASSESSING THE BURDEN OF CHRONIC HEART FAILURE (CHF) ON PATIENTS IN BRAZIL
Barbeau M1, Jackson J2, Cotton S2, Proenca C3, Calado F3, Lopes N4, MacPherson A5
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Biociências SA, Sao Paulo, Brazil, 5Dalhousie University, Halifax, NS, Canada

PCV19
E16
ASSESSING THE BURDEN OF CHRONIC HEART FAILURE (CHF) ON PATIENTS ARGENTINA
Barbeau M1, Jackson J2, Cotton S2, Proenca C3, Calado F3, Bianculli PM4, MacPherson A5
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Argentina S.A., Buenos Aires, Argentina, 5Dalhousie University, Halifax, NS, Canada

PCV20
E17
ASSESSING THE BURDEN OF CHRONIC HEART FAILURE (CHF) ON PATIENTS IN MEXICO
Barbeau M1, Jackson J2, Cotton S2, Proenca C3, Calado F3, Romo X4, MacPherson A5
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Farmacéutica S.A. de C.V, Mexico City, Mexico, 5Dalhousie University, Halifax, NS, Canada

PCV21
E18
QUALITY OF LIFE IMPROVEMENT IN A HEART FAILURE CLINICAL PROGRAM VS. CONVENTIONAL MANAGEMENT IN A SPECIALIZED CLINIC IN COLOMBIA
Saldarriaga C1, Gonzalez N2, Valencia J3, Orozco JJ4
1Universidad de Antioquia, Medellín, Colombia, 2Clinica CardioVID, Medellin, Colombia, 3Medtronic, Miami, FL, USA, 4Medtronic PLC, Medellín, Colombia

CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies
PCV22
F1
MODELLING THE BURDEN OF CARDIOVASCULAR DISEASE IN COLOMBIA AND THE IMPACT OF REDUCING MODIFIABLE RISK FACTORS
Ruiz Morales A1, Gagnon-Arpin I2, Dobrescu A2, Sutherland G2, Villa G3, Garcia Perlaza J4, Habib M5
1Pontifica Universidad Javeriana Medical School, Bogota, Colombia, 2The Conference Board of Canada, Ottawa, ON, Canada, 3Amgen, Zug, Switzerland, 4Amgen, Inc., Bogota, Colombia, 5Amgen, Inc., Thousand Oaks, CA, USA

PCV23
F2
POTENTIAL MORTALITY REDUCTION WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE IN ARGENTINA
Bianculli PM1, Volman S1, Barbeau M2, MacPherson A3, Haroun R4, Giorgi M5
1Novartis Argentina S.A., Buenos Aires, Argentina, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Dalhousie University, Halifax, NS, Canada, 4Novartis Pharma AG, Basel, Switzerland, 5Instituto Universitario CEMIC, Buenos Aires, Argentina

PCV24
F3
EVALUATION OF BARRIERS TO EFFECTIVE INSULIN THERAPY AMONG TYPE 2 DIABETES MELLITUS PATIENTS
Arooj S1, Masood I2, Naz M1, Amir S1, Nazir A1, Qamar-Uz-Zaman M2, Akbar J2
1The Islamia University Of Bahawalpur, Bahawalpur, Pakistan, 2The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PCV25
F4
PHARMATOOL: AN ECONOMIC AND EPIDEMIOLOGICAL CALCULATION TOOL TO AID PLANNING FOR REDUCING CARDIOVASCULAR MORBIDITY IN BRAZIL
Cazarim MS1, Nunes AA1, Aliste MJ2, Wu O3, Pereira LR1
1University of São Paulo, Ribeirão Preto, Brazil, 2University of Chile, Santiago, Chile, 3University of Glasgow, Glasgow, UK

PCV26
F5
TREATMENT PATTERNS OF CHRONIC HEART FAILURE (CHF) IN ARGENTINA
Bianculli PM1, Jackson J2, Cotton S2, Proenca C3, Calado F3, MacPherson A4, Barbeau M5
1Novartis Argentina S.A., Buenos Aires, Argentina, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada, 5Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV27
F6
TREATMENT PATTERNS OF CHRONIC HEART FAILURE (CHF) IN MEXICO
Romo X1, Jackson J2, Cotton S2, Proenca C3, Calado F3, MacPherson A4, Barbeau M5
1Novartis Farmacéutica S.A. de C.V, Mexico City, Mexico, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada, 5Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV28
F7
TREATMENT PATTERNS OF CHRONIC HEART FAILURE (CHF) IN BRAZIL
Lopes N1, Jackson J2, Cotton S2, Proenca C3, Calado F3, MacPherson A4, Barbeau M5
1Novartis Biociências SA, Sao Paulo, Brazil, 2Adelphi Real World, Bollington, Macclesfield, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada, 5Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.